Vancive Medical Technologies04.03.17
A line of transparent postoperative dressings designed to enhance patient care will be jointly introduced by Eloquest Healthcare Inc. and Vancive Medical Technologies, an Avery Dennison business at AORN in Boston, MA. The technology just received 510(k) clearance from the FDA.
The new dressings, called ReliaTect, incorporate BeneHold CHG, an innovative adhesive technology from Vancive Medical Technologies, that comfortably secures the dressing to the skin, absorbs fluids, and protects the site from external contaminants. The CHG contained within the adhesive preserves the dressings from microbial growth, making them ideally suited for postoperative sites. Eloquest Healthcare is the exclusive distributor of the dressings in the United States and Canada.
“The unique characteristics of the ReliaTect postoperative dressings make them a great complement to our growing portfolio and increases the value we are able to provide to our customers.” said Tim O’Halla, president and CEO for Eloquest Healthcare. “The BeneHold CHG adhesive technology delivers the combination of fluid management and sustained transparency with antimicrobial effect of chlorhexidine gluconate, offering clinicians a simple and innovative solution for postop site management.”
The ReliaTect dressings will be available in two sizes (small and large) and designed to be ideal for various postoperative sites.
“BeneHold CHG adhesive technology adds value to postoperative dressings,” said Kirsten Newquist, general manager for Vancive Medical Technologies. “The collaboration with Eloquest Healthcare brings together complementary resources, experience and expertise from each company. We look forward to working with Eloquest Healthcare to bring ReliaTect to market.”
Eloquest Healthcare and Vancive Medical Technologies will showcase the new Eloquest Healthcare ReliaTect dressings in booth #3019 at the AORN Global Surgical Conference & Expo, April 2-4 in Boston, MA. To learn more about the Eloquest Healthcare ReliaTect postoperative dressings with CHG, visit http://www2.eloquesthealthcare.com/ReliaTectLaunch.
The new dressings, called ReliaTect, incorporate BeneHold CHG, an innovative adhesive technology from Vancive Medical Technologies, that comfortably secures the dressing to the skin, absorbs fluids, and protects the site from external contaminants. The CHG contained within the adhesive preserves the dressings from microbial growth, making them ideally suited for postoperative sites. Eloquest Healthcare is the exclusive distributor of the dressings in the United States and Canada.
“The unique characteristics of the ReliaTect postoperative dressings make them a great complement to our growing portfolio and increases the value we are able to provide to our customers.” said Tim O’Halla, president and CEO for Eloquest Healthcare. “The BeneHold CHG adhesive technology delivers the combination of fluid management and sustained transparency with antimicrobial effect of chlorhexidine gluconate, offering clinicians a simple and innovative solution for postop site management.”
The ReliaTect dressings will be available in two sizes (small and large) and designed to be ideal for various postoperative sites.
“BeneHold CHG adhesive technology adds value to postoperative dressings,” said Kirsten Newquist, general manager for Vancive Medical Technologies. “The collaboration with Eloquest Healthcare brings together complementary resources, experience and expertise from each company. We look forward to working with Eloquest Healthcare to bring ReliaTect to market.”
Eloquest Healthcare and Vancive Medical Technologies will showcase the new Eloquest Healthcare ReliaTect dressings in booth #3019 at the AORN Global Surgical Conference & Expo, April 2-4 in Boston, MA. To learn more about the Eloquest Healthcare ReliaTect postoperative dressings with CHG, visit http://www2.eloquesthealthcare.com/ReliaTectLaunch.
